Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Study Phase: Phase 1
Recruitment Status: Recruiting
Start Date: April 03, 2018
End Date: November 30, 2026
BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
855-907-3286
First line of the email MUST contain the NCT# and Site #.
Inclusion Criteria:
- History of multiple myeloma with relapsed and refractory disease
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Must have measurable disease as determined by the central laboratory
Exclusion Criteria:
- Symptomatic central nervous system involvement of multiple myeloma
- Prior autologous stem cell transplant ≤ 3 months prior
- Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior
- History of concurrent second cancers requiring active, ongoing systemic treatment Other protocol-defined inclusion/exclusion criteria apply
-
Conditions:
- Multiple Myeloma
- Neoplasms, Plasma Cell